Feline Immune-Mediated Polyarthritis (Non-Erosive)

Feline immune-mediated polyarthritis (non-erosive) (IMPA) is an inflammatory joint disease in cats in which the immune system aberrantly targets the synovium of multiple joints simultaneously, yet does not produce the radiographic bone or cartilage destruction characteristic of erosive forms. It represents the most clinically important non-infectious, non-erosive arthropathy in cats and can be either idiopathic or secondary to an underlying systemic disease, infection, or drug exposure. The condition is considered rare, and most published data derive from small retrospective case series at referral institutions [1]. Despite its uncommon occurrence, the disease carries meaningful morbidity and requires prompt recognition and immunosuppressive management.

Classification

Non-erosive IMPA in cats is broadly divided into idiopathic and secondary (reactive) forms:

• ·Idiopathic IMPA: No identifiable underlying trigger is found after thorough diagnostic work-up. This mirrors idiopathic IMPA recognised in dogs and is the most common category identified in referral practice [1].
• ·Secondary (reactive) IMPA: The joint inflammation is driven by an immune response to an antigen originating outside the joint, including chronic infections (e.g., calicivirus, herpesvirus, Mycoplasma spp., Bartonella spp.), inflammatory diseases (e.g., IBD, stomatitis), neoplasia, or drug administration [1].

Pathological Mechanism

The fundamental lesion is immune complex–mediated synovitis. Antigen–antibody complexes (formed locally or deposited from the systemic circulation) activate complement and recruit neutrophils and macrophages into the synovial space. The resulting inflammatory cascade causes synovial hyperplasia, increased vascular permeability, and accumulation of proteinaceous joint fluid rich in inflammatory cells — predominantly non-degenerative neutrophils. Unlike erosive forms (e.g., feline rheumatoid-like arthritis), the inflammatory process remains confined to the synovium and joint capsule without invading periarticular bone or cartilage, explaining the absence of radiographic erosions. Immune dysregulation may involve altered T-cell regulation and upregulation of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), although feline-specific immunopathological data remain limited.

Predisposing Factors

Based on the largest published case series, castrated male cats appear over-represented (60%), though whether this reflects a true sex predisposition or referral/population bias is unclear [1]. No strong breed predisposition has been firmly established. Calicivirus has been implicated in transient polyarthritis, particularly in kittens following vaccination or natural infection.

Diagnosis of non-erosive IMPA is based on a combination of clinical findings, laboratory analysis of synovial fluid, radiography to exclude erosive disease, and ruling out infectious or other secondary causes.

Synovial Fluid Analysis (Gold Standard)

Arthrocentesis of multiple joints (typically ≥2, preferably ≥4 joints) is essential. Cytological hallmarks of IMPA include:

• ·Markedly elevated total nucleated cell count (typically >3,000–5,000 cells/µL; often >10,000–50,000 cells/µL in active disease)
• ·Neutrophilic pleocytosis with non-degenerate neutrophils constituting ≥90% of the differential
• ·Increased protein content; fluid appears turbid or yellow
• ·Absence of bacteria on Gram stain and negative culture (to exclude septic arthritis)

Haematology and Biochemistry

Systemic inflammatory changes are commonly documented [1]:

• ·Complete Blood Count: Neutrophilia and leukocytosis are expected; a stress leukogram is common. Mild normocytic normochromic anaemia (low HCT) may accompany chronic inflammation.
• ·Serum biochemistry: Hyperglobulinaemia (elevated GLOB) reflecting polyclonal gammopathy; hypoalbuminaemia (low ALB) due to systemic inflammation and negative acute-phase response. Mild elevations in ALT may be seen if hepatic involvement or drug effects are present. BUN and CREA should be assessed as baseline and to guide drug selection.
• ·Acute-phase proteins: Serum amyloid A (SAA) and alpha-1-acid glycoprotein may be elevated, supporting active inflammation.

Radiography

Radiographs of affected joints are mandatory to differentiate non-erosive from erosive IMPA. In non-erosive disease, findings are typically limited to periarticular soft-tissue swelling and joint effusion without subchondral bone lysis, periarticular erosions, or joint collapse [1].

Infectious Disease Screening

A thorough work-up for infectious and reactive causes is required before diagnosing idiopathic IMPA:

• ·PCR and serology for FIV, FeLV, calicivirus, Bartonella spp., Mycoplasma spp., Toxoplasma gondii
• ·Urine culture and thoracic/abdominal imaging to detect occult infection or neoplasia
• ·Antinuclear antibody (ANA) titre (positive in a subset, but not specific)

Confirmatory Criteria

A definitive diagnosis requires all of the following: (1) polyarticular joint effusion with neutrophilic synovial fluid cytology, (2) no radiographic evidence of erosion, (3) exclusion of septic arthritis and crystal arthropathy, and (4) exclusion or identification of an underlying cause.

Treatment strategy depends on whether IMPA is idiopathic or secondary. In secondary forms, addressing the underlying disease may lead to resolution of joint inflammation without or with minimal immunosuppression.

Immunosuppressive Therapy

Corticosteroids are the cornerstone of treatment for idiopathic non-erosive IMPA [1]:

• ·Prednisolone: Initial immunosuppressive dose of 2–4 mg/kg/day PO, tapered gradually over weeks to months based on clinical and laboratory response. This is the most commonly used first-line agent [1].
• ·Response is monitored by resolution of lameness, normalisation of body temperature, improvement in haematological and biochemical parameters, and repeat synovial fluid cytology when indicated.

Second-line / Steroid-sparing Agents are used when response to corticosteroids alone is inadequate or when side effects necessitate dose reduction [1]:

• ·Chlorambucil: An alkylating agent used as an adjunct in refractory cases
• ·Ciclosporin (cyclosporine): Calcineurin inhibitor used in cats intolerant of or unresponsive to prednisolone; dosing typically 5–7.5 mg/kg/day PO
• ·Leflunomide: Has been used in feline IMPA based on canine protocols; limited feline-specific data available
• ·Methotrexate and azathioprine: Occasionally described; azathioprine carries a significant risk of myelosuppression in cats and must be used with extreme caution if at all

Treatment of Secondary IMPA

Identification and management of the underlying cause is paramount. For example:

• ·Antibiotic therapy for concurrent Mycoplasma or Bartonella infection
• ·Dietary management and immunosuppression for concurrent IBD
• ·Discontinuation of a suspected causative drug

Supportive Care

• ·NSAIDs: Use with caution or avoid while on corticosteroids; may provide adjunctive analgesia during tapering phases in selected patients
• ·Joint supplementation: Omega-3 fatty acids and nutraceuticals (glucosamine/chondroitin) may provide modest benefit as adjuncts
• ·Rest and physiotherapy: Restricted activity during acute flares; controlled rehabilitation to maintain muscle mass during remission
• ·Monitoring: Regular haematology, biochemistry (including renal parameters given immunosuppressive drug nephrotoxicity risk), and clinical reassessment during treatment

Outcome Data

Based on the largest published multicentre retrospective study [1], the prognosis for feline non-erosive IMPA is guarded to fair, with meaningful rates of both remission and relapse:

• ·Overall survival: The majority of cats in the referenced cohort survived to follow-up, but a subset were euthanased or died during the study period, reflecting the serious nature of this disease in some individuals [1].
• ·Relapse: Relapse of clinical signs is a recognized challenge; a proportion of cats required ongoing or reinstated immunosuppressive therapy after initial improvement [1].
• ·Remission: Some cats achieved complete clinical remission and were successfully weaned off all medications; the proportion achieving drug-free remission versus requiring lifelong therapy varied across cases [1].
• ·Euthanasia: A subset of cats in the retrospective series were euthanased, typically due to failure to respond to treatment, unacceptable quality of life due to persistent lameness, or complications of underlying disease [1].

Prognostic Factors

Cats with an identifiable and treatable underlying cause (secondary IMPA) may carry a better prognosis if the primary disease is controlled. Idiopathic cases tend to have a more unpredictable course. Early recognition and prompt institution of appropriate immunosuppression are likely to positively influence outcome, though specific multivariate prognostic analyses are limited by small case numbers [1].

Limitations

The total published case series remain small (n=20 in the primary reference [1]), and larger prospective studies are needed to generate robust survival statistics. Precise mortality percentage figures are not explicitly quantified in the available literature.

Current Limitations

There is no established preventive protocol specifically for feline non-erosive IMPA, reflecting its immune-mediated (rather than directly infectious) pathogenesis and the incomplete understanding of its triggers.

General Recommendations

• ·Vaccination: Routine vaccination against feline calicivirus (FCV) is recommended as part of core vaccination protocols, given the recognised association between FCV and transient vaccine-associated or natural-infection polyarthritis, particularly in kittens. Minimising modified-live calicivirus vaccine reactions through appropriate vaccine selection may reduce this specific trigger.
• ·Infection surveillance: Early detection and treatment of chronic infections (FIV, FeLV, Mycoplasma, Bartonella) that can act as reactive IMPA triggers may reduce secondary cases.
• ·Drug monitoring: Careful monitoring of cats receiving medications known to potentially trigger immune-mediated disease (e.g., certain antibiotics), with prompt discontinuation if signs of polyarthritis develop.
• ·Routine health checks: Prompt investigation of unexplained lameness, fever, or stiffness — particularly when polyarticular — enables early diagnosis and reduces the duration of uncontrolled inflammation.
• ·Neutering status: The observed over-representation of castrated males [1] does not currently generate actionable preventive recommendations, but warrants further epidemiological investigation.

METADATA